8-K: N2OFF to Acquire MitoCareX Bio, Expanding into Cancer Therapeutics

N2OFF, a clean tech company, has signed a definitive agreement to acquire MitoCareX Bio, a drug discovery company targeting resistant cancers, marking its entry into the biotech sector.

Summary

• N2OFF, Inc. has entered into a definitive agreement to acquire MitoCareX Bio Ltd., a biotech company focused on drug discovery for cancer therapeutics.
• The acquisition will be executed through a securities purchase and exchange agreement with SciSparc Ltd., Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri (the Sellers).
• N2OFF will purchase 4,961 shares from SciSparc for $700,000 and exchange additional shares with all Sellers for common stock totaling 40% of N2OFF's fully diluted capital stock.
• The Sellers will collectively be entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years.
• Following the closing of the deal, MitoCareX will become a wholly-owned subsidiary of N2OFF, with its board reconstituted by N2OFF appointees.
• The transaction is contingent upon approval by N2OFF's stockholders.
• The Sellers may also receive milestone-based issuances of up to 25% of N2OFF's common stock on a fully diluted basis.
• N2OFF is committed to financially support MitoCareX's operations for the first two years post-acquisition, including an initial cash investment of $1,000,000.
• The global Cancer Therapeutics and Biotherapeutics market was valued at $194.1B in 2024 and is expected to reach $344.1B by 2031.

Sentiment

Score: 7

Explanation: The document presents a positive outlook due to N2OFF's expansion into the biotech sector and the potential of MitoCareX's drug discovery platform. However, risks associated with stockholder approval, integration challenges, and clinical trial outcomes temper the overall sentiment.

Positives

• N2OFF diversifies its portfolio by entering the high-growth biotech sector.
• MitoCareX brings a computationally advanced drug discovery platform targeting hard-to-treat cancers.
• N2OFF secures full ownership of MitoCareX, allowing for complete control and integration.
• The milestone-based issuance structure aligns the Sellers' interests with N2OFF's long-term success.
• The acquisition provides MitoCareX with financial stability and resources for ongoing research and development.
• N2OFF gains access to MitoCareX's advanced in-vitro screening systems related to mitochondria.

Negatives

• The acquisition is subject to stockholder approval, introducing a potential risk of deal termination.
• The Sellers' entitlement to 30% of N2OFF's financing proceeds could dilute future earnings for existing shareholders.
• Integrating MitoCareX's operations and technology may present challenges and require significant management attention.
• The success of MitoCareX's drug discovery efforts is uncertain and depends on future clinical trials and regulatory approvals.
• The milestone payments are dependent on the Sellers achieving certain milestones by December 31, 2028, such that if a specific Milestone is not achieved and therefore the right to receive the respective number of shares of Additional Company Stock issuable upon the achievement of such Milestone is not earned by December 31, 2028, the right to receive the number of shares of Additional Company Stock attributable to any such non-achieved Milestone pursuant to the Agreement will terminate.

Risks

• Failure to obtain stockholder approval could prevent the acquisition from proceeding.
• Integration challenges may hinder the realization of expected synergies between N2OFF and MitoCareX.
• Clinical trial failures or regulatory setbacks could negatively impact MitoCareX's drug development pipeline.
• Competition in the cancer therapeutics market could limit MitoCareX's market share and profitability.
• The milestone payments are dependent on the Sellers achieving certain milestones by December 31, 2028, such that if a specific Milestone is not achieved and therefore the right to receive the respective number of shares of Additional Company Stock issuable upon the achievement of such Milestone is not earned by December 31, 2028, the right to receive the number of shares of Additional Company Stock attributable to any such non-achieved Milestone pursuant to the Agreement will terminate.
• The Sellers' entitlement to 30% of N2OFF's financing proceeds could dilute future earnings for existing shareholders.

Future Outlook

The company expects the acquisition of MitoCareX to provide operational and business opportunities, and potential benefits to N2OFF if the transaction is approved by the stockholders of N2OFF.

Management Comments

• Mr. Amitay Weiss, Chairman of the Board of Directors of N2OFF, also serves as the Chairman of the Board of Directors of SciSparc.

Industry Context

The acquisition positions N2OFF in the rapidly growing cancer therapeutics market, estimated at $194.1B in 2024 and projected to reach $344.1B by 2031, according to Coherent Market Insights.

Comparison to Industry Standards

• The acquisition of a drug discovery company by a clean tech company is unusual, as most acquisitions in the biotech space are made by established pharmaceutical companies.
• Comparable companies in the cancer therapeutics market include Roche, Novartis, and Merck, which have made numerous acquisitions to expand their pipelines.
• The $700,000 cash payment and the issuance of 40% of N2OFF's fully diluted capital stock is a relatively small deal compared to other acquisitions in the pharmaceutical industry.
• The milestone-based payments are a common structure in biotech acquisitions, aligning the interests of the sellers with the success of the acquired company.

Related Party Transactions

• Alon is the brother of Kfir Silberman, the owner of Pure Capital, a stockholder and lender of the Company owning 9.78% of the Common Stock of the Company as of the date of this Current Report on Form 8-K, and each of Amitay Weiss and Liat Sidi, board members of the Company, also serve as board members of SciSparc.

Stakeholder Impact

• Shareholders of N2OFF may experience dilution due to the issuance of new shares to the Sellers.
• Employees of MitoCareX will become part of N2OFF and may experience changes in management and operations.
• Customers and partners of MitoCareX may benefit from increased resources and support from N2OFF.
• Suppliers and creditors of MitoCareX will now be dealing with N2OFF as the parent company.

Next Steps

• Obtain approval from N2OFF's stockholders for the acquisition.
• Close the transaction and integrate MitoCareX as a wholly-owned subsidiary.
• Reconstitute the board of directors of MitoCareX with N2OFF appointees.
• Provide financial support to MitoCareX for ongoing research and development.
• Pursue milestone achievements to trigger additional stock issuances to the Sellers.

Key Dates